1-5 of 5
Fanny Angelot-Delettre, PhD
Close
Sort by
Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Harbors Frequent Splicesosome Mutations That Cause Aberrant RNA Splicing Affecting Genes Critical in pDC Differentiation and Function

Katsuhiro Togami, MD PhD, Vikas Madan, PhD, Jia Li, PhD, Alexandra-Chloe Villani, PhD, Siranush Sarkizova, BS, Mahmoud Ghandi, PhD, Kevin Buczkowski, BS, Yvonne Li, PhD, Sabeha Biichle, BS, Fanny Angelot-Delettre, PhD, Michael Seiler, PhD, Silvia Buonamici, PhD, Justin Taylor, MD, Omar Abdel-Wahab, MD, Peter S Hammerman, MD PhD, Nir Hacohen, PhD, Henry Yang, PhD, Francine Garnache-Ottou, PhD, H. Phillip Koeffler, MD PhD, Andrew A. Lane, MD PhD
Journal: Blood
Blood (2016) 128 (22): 738.
https://doi.org/10.1182/blood.V128.22.738.738
Published: 2016
Journal Articles

Liver X Receptor Agonists: A Potential Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm

Adam Ceroi, PhDSTUDENT, Francine Garnache-ottou, PhD, Anne Roggy, PhDSTUDENT, Fanny Angelot-Delettre, PhD, Laure Philippe, MDcal student, Afag Asgarova, PhDstudent, Francis Bonnefoy, PhD, Cécile Chagué, SM Student, Sabeha Biichle, Jean-Paul Remy-Martin, ING, Claude Preudhomme, MD PhD, Christophe Roumier, MD, Elizabeth Macintyre, MD PhD, Laurent Lagrost, PhD, David Masson, PhD, Philippe Saas, PhD
Journal: Blood
Blood (2015) 126 (23): 4933.
https://doi.org/10.1182/blood.V126.23.4933.4933
Published: 2015
Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Amanda L Christie, B.S., Yvonne Li, PhD, Katsuhiro Togami, MD, Mahmoud Ghandi, PhD, Alexandra N. Christodoulou, M.S., Kevin Buczkowski, Fanny Angelot-Delettre, PhD, Sabeha Biichle, Janice Chen, PhD, Christopher L. Brooks, PhD, David M. Weinstock, MD, Francine Garnache-Ottou, PhD, Peter S Hammerman, MD PhD, Andrew A Lane, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3797.
https://doi.org/10.1182/blood.V126.23.3797.3797
Published: 2015
Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD
Journal: Blood
Blood (2013) 122 (21): 2682.
https://doi.org/10.1182/blood.V122.21.2682.2682
Published: 2013
Journal Articles

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Fanny Angelot-Delettre, PhD, Arthur E. Frankel, MD, Jen Sing Liu, PhD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Bernard Drenou, MD, PhD, Mark L. Jacobson, MA, Thomas P. Cirrito, PhD, Arkam Yazid, MD, Eric Deconinck, MD, PhD, Christopher L. Brooks, PhD, Philippe Saas, PhD, Francine Garnache Ottou, PhD
Journal: Blood
Blood (2011) 118 (21): 2588.
https://doi.org/10.1182/blood.V118.21.2588.2588
Published: 2011